Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results

Source: Streetwise Reports


December 7, 2017 ( Newswire) This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.

"Initial results from ten evaluable patients in the DPX-Survivac plus 100 mg epacadostat dosing cohort demonstrate a disease control rate of 70%, including partial responses (PR, defined as ≥30% decrease in tumor lesion size) in 30% of the patients (three out of ten)," a Dec. 5 press release from Immunovaccine Inc. (IMV:TSX; IMMVF:OTCQX) stated.

DPX-Survivac is being used "in combination with Incyte Corp. (INCY:NASDAQ) IDO1 enzyme inhibitor epacadostat, and low-dose cyclophosphamide" in a Phase 1b study in advanced ovarian cancer, the company explained. The candidate employs the DepoVax drug-delivery technology, and has fast-track status from the FDA "as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication," Immunovaccine noted.

In addition, Immunovaccine relayed the Phase 1b safety results: "To date, the combination also exhibited a well-tolerated safety profile, with the majority of adverse events (AEs) reported as Grade 1 and Grade 2, and only one potential treatment-related AE."

Andre Uddin of Mackie Research, in a Dec. 5 research report, noted, "of the ten ovarian cancer patients that completed the treatment with DPX-Survivac plus 100 mg Epacadostat, 3 had partial responses and 4 had stable diseases—yielding an impressive objective response rate."

The Mackie analyst went on to state, "The newly announced positive top-line results should justify the combined use of DPX-Survivac and Epacadostat in treating recurrent ovarian cancer and should help facilitate a licensing deal." Uddin also noted Mackie's belief that "immunotherapy agents that improve the rates of durable remission and/or have activity against chemo-resistant disease are likely to be highly sought after by big pharma."

Mackie rates Immunovaccine a speculative buy with a price target of $2.80 per share (up from $2.20). Shares currently trade at around $1.79.

In his Dec. 5 research report, Douglas Loe of Echelon Wealth Partners wrote that while it's still "early days" for the DPX-Survivac therapy, "encouraging signals that the immune therapy works as expected in ovarian cancer are already available." His company increased its one-year price target to $3.25 per share from $2.75, and maintains a speculative buy rating.

The Immunovaccine trial data indicated T-cell activation, which prompted this comment from Loe: "Importantly, we were encouraged to see that antigen-specific T-cell activation was apparent in the majority of treated patients, and with magnitude of T-cell response correlating well with magnitude of tumor regression."

In addition, Loe noted: "We cannot read Incyte's mind, but we see ample justification for locking in economic interests in DPX-Survivac, perhaps once Phase I/II ovarian cancer testing concludes by mid-F2018."

Loe also commented on the number of milestones on the horizon, including a second Phase 1/2 trial in ovarian cancer, a Phase 1/2 trial "combining DPX-Survivac with Keytruda/pembrolizumab," also in ovarian cancer, a Phase 1/2 trial in HPV-related cancer, and trials of DPX-RSV, also formulated using Immunovaccine's DepoVax delivery platform, in respiratory syncytial virus.

"Individuals with recurrent ovarian cancer, in particular, have not yet benefited from immunotherapy treatment breakthroughs in the way that those with other hard-to-treat cancers have," said CEO Frederic Ors in the company's announcement. "We are excited by the potential of DPX-Survivac to increase the number of individuals who may benefit from novel combination immunotherapies, and look forward to our continued work with Incyte and our other partners to increase the treatment options for such patients."

Read what other experts are saying about:


1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Immunovaccine. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Learn more about publishing your news release on the newswire

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Please read privacy policy: